How is it possible that half of all gynecologists are still prescribing hormone replacement therapy to their patients for uses that are clearly unsupported by evidence – despite the alarming warnings of the largest randomized, placebo-controlled trial of HRT ever performed?
This reality is “curious”, according to Dr. Adriane Fugh-Berman at Georgetown University Medical Center, in a new study* examining 340 medical journal articles about HRT. Her research was published yesterday in the journal, Public Library of Science Medicine.
But even more curious are her findings that the majority of the doctors who have written pro-HRT papers for medical journals have been funded by the very drug companies that manufacture hormone replacement drugs.
These companies were financially hurt by 2002 results of the massive Women’s Health Initiative study, which meant an almost immediate catastrophic loss of sales revenue for manufacturers of all HRT drugs. Prescriptions dropped by 80% – a major blow to companies like Wyeth Pharmaceuticals, whose HRT drugs Prempro and Premarin had earned the company over $2 billion just one year earlier. (That still puts the net gain well ahead for the company, who has now settled a third of the pending lawsuits from women who developed breast cancer while on Prempro, after the company set aside over $772 million to resolve legal claims, according to Bloomberg).